A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP STUDY TO EVALUATE THE SAFETY AND EFFICACY OF LAMOTRIGINE 200-400MG/DAY COMPARED WITH PLACEBO IN SUBJECTS WITH PAINFUL DIABETIC NEUROPATHY
Latest Information Update: 07 Apr 2022
At a glance
- Drugs Lamotrigine (Primary)
- Indications Diabetic neuropathies; Neuropathic pain
- Focus Therapeutic Use
- 31 Mar 2022 This trial has been completed in Denmark (Global end date: 17 Feb 2005).
- 11 Dec 2012 New trial record